Cornerstone Therapeutics Inc. (CRTX)
-NasdaqCM 8.54 
0.40(4.47%) 4:00PM EDT
| Prev Close: | 8.94 |
|---|
| Open: | 8.55 |
|---|
| Bid: | N/A |
|---|
| Ask: | 31.35 x 8900 |
|---|
| 1y Target Est: | 14.00 |
|---|
| Beta: | 0.44 |
|---|
| Next Earnings Date: | 5-Aug-13 |
|---|
| Day's Range: | 8.48 - 8.93 |
|---|
| 52wk Range: | 3.10 - 9.13 |
|---|
| Volume: | 85,729 |
|---|
| Avg Vol (3m): | 67,113 |
|---|
| Market Cap: | 225.68M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -0.29 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- CORNERSTONE THERAPEUTICS INC FinancialsEDGAR Online Financials(Fri, May 17)
- Significant Near-Term Top-Line Data Catalyst And Platform Technology Should Propel Insmedat Seeking Alpha(Tue, May 14)
- Cornerstone Therapeutics Management Discusses Q1 2013 Results - Earnings Call Transcriptat Seeking Alpha(Thu, May 9)
- CORNERSTONE THERAPEUTICS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements andEDGAR Online(Thu, May 9)
- Q1 2013 Cornerstone Therapeutics Inc. Earnings Release - Before Market OpenCCBN(Thu, May 9)
- Cornerstone Therapeutics Reports First Quarter 2013 Financial ResultsMarketwired(Thu, May 9)
- Cornerstone Therapeutics Acquires Exclusive U.S. Marketing Rights to PERTZYE(R) (pancrelipase) for Treatment of Exocrine Pancreatic Insufficiency in Patients With Cystic FibrosisMarketwired(Thu, May 9)
- REMINDER: Cornerstone Therapeutics to Host First Quarter 2013 Conference CallMarketwired(Wed, May 8)
- Cornerstone Therapeutics to Host First Quarter 2013 Conference CallMarketwired(Thu, May 2)
- [video] Nasdaq Midday Updateat CNBC(Tue, Apr 2)
- Cornerstone Therapeutics Inc. Announces Retention of AdvisorsMarketwired(Wed, Mar 20)
- CORNERSTONE THERAPEUTICS INC Files SEC form 8-K, Other Events, Financial Statements and ExhibitsEDGAR Online(Wed, Mar 20)
- New Star Analyst Rankings for Cornerstone Therapeutics Inc.StarMine(Sat, Mar 16)
- CORNERSTONE THERAPEUTICS INC Files SEC form 8-K, Entry into a Material Definitive AgreementEDGAR Online(Thu, Mar 14)
- Cornerstone Therapeutics Management Discusses Q4 2012 Results - Earnings Call Transcriptat Seeking Alpha(Thu, Mar 14)
Key Statistics
| Forward P/E (1 yr): | 18.57 |
|---|
| P/S (ttm): | 1.79 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | 0.68 |
|---|
| Quarterly EPS Est
(Jun-13)
: | 0.14 |
|---|
| Mean Recommendation*: | 1.0 |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
Cornerstone Therapeutics Inc., a specialty pharmaceutical company, engages in the acquisition, development, and commercialization of prescription pharmaceutical drugs for the hospital and adjacent specialty markets.
View More